#高警訊藥品

Hypoglycemia Intravenous feeding of patient

Intravenous Nutritional Therapy

1. Maximum effect: (Treatment of hyperkalemia, IV) 30 minutes
2. Metabolism: Metabolized to carbon dioxide and water

1. Hypersensitivity to dextrose, corn or corn products, or any component of the formulation
2. Delirium tremens (if dehydrated); severe dehydration
3. Clinically significant hyperglycemia; anuria; hepatic coma

Appropriate use of dextrose injection would not be expected to cause adverse developmental outcomes to the fetus when used during pregnancy.

According to the manufacturer, the decision to breastfeed during therapy should consider the risk and benefits.

Hyperglycemia, Injection site extravasation, Hyperosmolarity, Hypervolemia, Cerebral hemorrhage, Cerebral ischemia, Pulmonary edema

10 to 20ml each time, one to several times per day (IV)

IV dose is dependent upon the age, weight and clinical condition of the patient; particular caution in pediatric patients, neonates, and low birth weight infants

There are no specific dosage adjustments provided in the manufacturer's labeling; however, dextrose is excreted by the kidney, and closer monitoring for adverse effects may be warranted in patients with renal impairment.

There are no dosage adjustments provided in the manufacturer's labeling.

Store at controlled room temperature, between 15 and 25 degrees C